RECURSION PHARMACEUTICALS, INC. Insider Trading Activity
Every SEC Form 4 insider transaction reported for RECURSION PHARMACEUTICALS, INC. (RXRX), sourced directly from SEC EDGAR and updated as new filings are accepted.
By Trabud · Insider-trading data from SEC EDGAR
Latest filing:
Compiled automatically from SEC EDGAR Form 4 filings and refreshed daily. Figures count purchases (code P) and sales (code S) only — not grants, option exercises, or gifts. How this page is built. Not investment advice.
Quick Answer
Are RXRX insiders buying or selling?
In the last 12 months, RECURSION PHARMACEUTICALS, INC. insiders reported 0 open-market purchases ($0) and 36 sales ($8.2M) — net selling of $8.2M. Since April 2021, Trabud has recorded 237 Form 4 filings for RXRX: 19 buys ($64.7M) and 218 sells ($66.2M).
Source: SEC EDGAR Form 4
What stands out
- No RECURSION PHARMACEUTICALS, INC. insider made an open-market purchase in the last 12 months; the 36 reported open-market sales totaled $8.2M.
Key Statistics (April 2021 – Oct 7, 2026)
Total Form 4 filings
237
SEC EDGAR
Insider filers
14
Insider buys (19)
$64.7M
Insider sells (218)
$66.2M
Insider sentiment
Net sellingNet insider flow of $1.5M in net selling since April 2021, and $8.2M in net selling over the last 12 months.
Recent RXRX insider transactions
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| Oct 7, 2026 | Blake Borgeson | Director | Sale | 50.0K | $4.84 | $242.0K | SEC ↗ |
| Oct 7, 2026 | Robert Hershberg | Director | Sale | 25.0K | $5.00 | $125.0K | SEC ↗ |
| Sep 10, 2026 | Najat Khan | CEO and President | Sale | 22.4K | $3.52 | $78.8K | SEC ↗ |
| Sep 2, 2026 | Blake Borgeson | Director | Sale | 30.0K | $3.34 | $100.2K | SEC ↗ |
| Aug 6, 2026 | Blake Borgeson | Director | Sale | 30.0K | $3.25 | $97.5K | SEC ↗ |
| Jul 9, 2026 | Blake Borgeson | Director | Sale | 40.0K | $3.96 | $158.5K | SEC ↗ |
| Jun 22, 2026 | Namandje Bumpus | Director | Sale | 4.0K | $3.18 | $12.6K | SEC ↗ |
| Jun 5, 2026 | Christopher Gibson | Director | Sale | 40.0K | $3.62 | $144.8K | SEC ↗ |
| Jun 5, 2026 | Najat Khan | CEO and President | Sale | 23.6K | $3.58 | $84.5K | SEC ↗ |
| Jun 4, 2026 | Namandje Bumpus | Director | Sale | 4.4K | $3.54 | $15.5K | SEC ↗ |
| Jun 4, 2026 | Blake Borgeson | Director | Sale | 30.0K | $3.68 | $110.4K | SEC ↗ |
| May 27, 2026 | Christopher Gibson | Director | Sale | 40.0K | $3.08 | $123.2K | SEC ↗ |
| May 8, 2026 | Christopher Gibson | Director | Sale | 40.0K | $3.37 | $134.8K | SEC ↗ |
| May 7, 2026 | Blake Borgeson | Director | Sale | 30.0K | $3.52 | $105.6K | SEC ↗ |
| Apr 24, 2026 | Christopher Gibson | Director | Sale | 40.0K | $3.61 | $144.4K | SEC ↗ |
| Apr 8, 2026 | Christopher Gibson | Director | Sale | 40.0K | $3.10 | $124.0K | SEC ↗ |
| Apr 8, 2026 | Blake Borgeson | Director | Sale | 30.0K | $3.10 | $93.0K | SEC ↗ |
| Mar 25, 2026 | Christopher Gibson | Director | Sale | 40.0K | $3.25 | $130.0K | SEC ↗ |
| Mar 18, 2026 | Ben R Taylor | Chief Financial Officer | Sale | 8.0K | $3.39 | $27.0K | SEC ↗ |
| Mar 11, 2026 | Najat Khan | CEO and President | Sale | 28.3K | $3.35 | $94.7K | SEC ↗ |
| Mar 4, 2026 | Blake Borgeson | Director | Sale | 170.0K | $3.46 | $588.2K | SEC ↗ |
| Feb 20, 2026 | Christopher Gibson | Director | Sale | 40.0K | $3.46 | $138.4K | SEC ↗ |
| Feb 20, 2026 | Ben R Taylor | Chief Financial Officer | Sale | 13.4K | $3.08 | $41.4K | SEC ↗ |
| Feb 6, 2026 | Christopher Gibson | Director | Sale | 40.0K | $4.12 | $164.8K | SEC ↗ |
| Feb 6, 2026 | Blake Borgeson | Director | Sale | 220.0K | $4.20 | $924.0K | SEC ↗ |
Showing the 25 most recent of 237 Form 4 filings for RECURSION PHARMACEUTICALS, INC..
Most active RXRX insiders
- Christopher Gibson76 filings
- Blake Borgeson65 filings
- Tina Marriott27 filings
- Mubadala Investment Co PJSC18 filings
- Michael Secora17 filings
Ask anything about RXRX insider activity
Use Trabud's AI agent to query RECURSION PHARMACEUTICALS, INC.'s Form 4 history in plain English — "Show me RXRX CEO purchases this year" or compare it against any other ticker.
Open the AI agentRXRX insider trading FAQ
Are RECURSION PHARMACEUTICALS, INC. insiders buying or selling?
In the last 12 months, RECURSION PHARMACEUTICALS, INC. insiders reported 0 open-market purchases ($0) and 36 sales ($8.2M) — net selling of $8.2M. Since April 2021, Trabud has recorded 237 Form 4 filings for RXRX: 19 buys ($64.7M) and 218 sells ($66.2M). Over the full record that is net selling of $1.5M.
How many insiders trade RXRX stock?
14 distinct insider filers — officers, directors, 10%+ owners, and investment groups filing jointly — have reported Form 4 transactions for RECURSION PHARMACEUTICALS, INC.. The most recent filing was accepted on Oct 7, 2026.
Where does Trabud get RXRX insider trading data?
All RXRX insider trading data comes directly from official SEC EDGAR Form 4 filings, which corporate insiders must submit within two business days of a transaction under Section 16(a) of the Securities Exchange Act of 1934.